"Receptor, EphA2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An Eph family receptor found abundantly in tissues of epithelial origin. It is expressed in a diverse array of tissues during embryonic development, suggesting that it may play a role in embryogenesis. In adult tissues high levels of the receptor are expressed in the LUNG; SKIN; SMALL INTESTINE and OVARY.
| Descriptor ID |
D036104
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.850.100 D12.776.543.750.630.500.100
|
| Concept/Terms |
Receptor, EphA2- Receptor, EphA2
- Epithelial Cell Kinase Protein
- EphA2 Receptor
- EphA2-Tyrosine Kinase
- EphA2 Tyrosine Kinase
- EphA2 Receptor Tyrosine Kinase
- EphA2 Protein
- Mammary-Derived Tyrosine Kinase 2
- Mammary Derived Tyrosine Kinase 2
|
Below are MeSH descriptors whose meaning is more general than "Receptor, EphA2".
Below are MeSH descriptors whose meaning is more specific than "Receptor, EphA2".
This graph shows the total number of publications written about "Receptor, EphA2" by people in this website by year, and whether "Receptor, EphA2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, EphA2" by people in Profiles.
-
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. J Clin Oncol. 2024 Oct 10; 42(29):3443-3452.
-
Identification of potent pan-ephrin receptor kinase inhibitors using DNA-encoded chemistry technology. Proc Natl Acad Sci U S A. 2024 May 07; 121(19):e2322934121.
-
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2).
-
Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci. 2023 Feb 15; 24(4).
-
Gastric epithelial attachment of Helicobacter pylori induces EphA2 and NMHC-IIA receptors for Epstein-Barr virus. Cancer Sci. 2021 Nov; 112(11):4799-4811.
-
MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021 10; 163(1):181-190.
-
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
-
Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112.
-
Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther. 2021 04; 28(3-4):321-334.
-
Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene. 2019 03; 38(12):2135-2150.